SCR7 --- NHEJ inhibitor


Catalog No. size PriceQuantity
M60082-2D 10 mM DMSO (0.598 mL) $129
M60082-2S 2 mg solid $129
M60082-10S 10mg solid $529

Description

SCR7 is a potent and selective inhibitor of non-homologous end joining (NHEJ). It inhibits joining of DSBs in cell-free DNA repair system, blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I, thereby leading to accumulation of DSBs within the cells, culminating into cytotoxicity. SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. More importantly, SCR7 impedes tumor progression in mouse models, and when co-administered with DSB-inducing therapeutic modalities it enhances their sensitivity significantly. In addition, SCR7 can promote the efficiency of HDR 4–5-fold for CRISPR editing in both human and mouse cell lines.

Product information

CAS Number: 1533426-72-0

Molecular Weight: 334.39

Formula: C18H14N4OS

Synonym:

MFCD28900670

Related CAS Number:

1533426-89-9 (SCR7 Sodium)

1533426-90-2 (SCR7 potassium)

1417353-16-2 (SCR7 E/S)

2321382-88-9 (SCR7 E, E/S)

Chemical Name: 5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol

Smiles: OC1=NC(S)=NC(N=CC2C=CC=CC=2)=C1N=CC1C=CC=CC=1 |t:7,18|

InChiKey: NEEVCWPRIZJJRJ-AYKLPDECSA-N

InChi: InChI=1S/C18H14N4OS/c23-17-15(19-11-13-7-3-1-4-8-13)16(21-18(24)22-17)20-12-14-9-5-2-6-10-14/h1-12H,(H2,21,22,23,24)/b19-11+,20-12+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 50 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Powder: 4oC 1 year

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: DMSO: 4oC 3 month

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

SCR7 was used at 20-150 µM final concentration in vitro and in cellular assays for anti-cancer. SCR7 was used at 1 µM final concentration in CRISPR editing.

In Vivo:

SCR7 was intraperitoneally (IP) dosed to mice at 20 mg/kg once per day.

References:

  1. Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. (2012) Cell. 151(7):1474-87.
  2. Chu VT, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. (2015) Nat Biotechnol. In press.

Products are for research use only. Not for human use.


Documents

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed